Cormedix Inc (CRMD) 8.61 $CRMD Capricor's CAP-1002 Gets

New Post Public Reply Private Reply Replies (0) Message Board

Apr 26, 2015 at 5:23 PM

Cormedix Inc (CRMD) 8.61 $CRMD

Capricor's CAP-1002 Gets Orphan Drug Status in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 4:53PM CDT
Capricor's (CAPR) CAP-1002 has been granted orphan drug status in the U.S. for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy.
CRMD: 8.61 (-0.22), BIIB: 401.71 (-28.57), CAPR: 7.25 (-0.75), AVEO: 1.92 (-0.08)

Ultragenyx Announces Positive Data from Triheptanoin Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 3:36PM CDT
Ultragenyx (RARE) announced positive data from an investigator-sponsored study on triheptanoin for glucose transporter type-1 deficiency syndrome.
CRMD: 8.61 (-0.22), BIIB: 401.71 (-28.57), RARE: 69.65 (+0.75), AVEO: 1.92 (-0.08)

CorMedix Presents Data from Neutrolin® Post Marketing Surveillance Study At Two Medical Conferences
PR Newswire - Thu Apr 23, 7:00AM CDT
CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, today announced presentations on Neutrolin® post marketing surveillance data at the 9th Congress of Vascular Access Society in Barcelona and the National Kidney Foundation Spring Clinical Meeting in Dallas.
CRMD: 8.61 (-0.22)

The Health of Healthcare Companies: Complementary Research on Landmark Bancorp, Genetic Technologies, Novogen, CorMedix, and BioCryst
PR Newswire - Thu Apr 23, 6:40AM CDT
Editor Note: For more information about this release, please scroll to bottom.
CRMD: 8.61 (-0.22), GENE: 4.70 (-0.13), LARK: 25.20 (-0.45), BCRX: 10.35 (-0.18), NVGN: 6.54 (-0.01)

Immunomedics (IMMU) Provides Update on Lead ADC Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 1:45PM CDT
Immunomedics, Inc. (IMMU) provided an update on its lead ADC candidate, sacituzumab govitecan.
CRMD: 8.61 (-0.22), BIIB: 401.71 (-28.57), IMMU: 4.09 (-0.02)

Illumina (ILMN) Tops Q1 Earnings, Revenues; EPS View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 9:15AM CDT
Illumina (ILMN) has started off 2015 on a positive note with remarkable first-quarter results, which mark the 14th consecutive quarter of sequential revenue growth.
CRMD: 8.61 (-0.22), BIIB: 401.71 (-28.57), CYTX: 0.99 (+0.01), ILMN: 189.59 (-3.01)

Actavis' Botox Upper Limb Spasticity Label Expanded by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 3:08PM CDT
Actavis' (ACT) Botox has been granted further FDA approval; adds upper limb spasticity to its label.
CRMD: 8.61 (-0.22), BIIB: 401.71 (-28.57), ACT: 295.41 (-2.95), AVEO: 1.92 (-0.08)

4 Stocks Under $10 Making Big Moves
at The Street - Thu Apr 16, 1:11PM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
CRMD: 8.61 (-0.22), MCEP: 6.38 (+0.12), NTLS: 5.42 (-0.15), OCLS: 0.85 (+0.03)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Apr 09, 8:11AM CDT

MEMP: 17.27 (-0.14), CRMD: 8.61 (-0.22), INO: 10.35 (-0.25), AMCN: 4.95 (-0.05), QURE: 26.09 (-0.28), ALTR: 40.89 (-1.20), BIOS: 5.26 (+0.01), NVGN: 6.54 (-0.01), ZNGA: 2.52 (-0.01), DGLY: 13.88 (+0.39), INFN: 20.15 (+0.81), EXEL: 3.08 (-0.02)

CorMedix Institutes Program to Reduce Neutrolin® Cost of Goods; Reports on Strategic Review Process Managed by Evercore
PR Newswire - Thu Apr 09, 7:00AM CDT
CorMedix Inc. (NYSE MKT: CRMD), a global biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, today announced a significant new program aimed at enhancing long term market competitiveness by substantially reducing the cost of goods of Neutrolin® Catheter Lock Solution through a more efficient, custom synthesis of the active ingredient taurolidine.
CRMD: 8.61 (-0.22)

CorMedix: High Probability Of Phase 3 Success?
Pharma Investor - at Seeking Alpha - Wed Apr 08, 12:49PM CDT

CRMD: 8.61 (-0.22)

Healthcare stock screen of the month: Price extended, poor fundamentals
Seeking Alpha - at Seeking Alpha - Wed Apr 08, 12:05PM CDT

CRMD: 8.61 (-0.22), ADXS: 23.34 (-0.27), CYTX: 0.99 (+0.01), CNDO: 3.97 (-0.14), AMRN: 2.33 (-0.10), AVEO: 1.92 (-0.08), NVGN: 6.54 (-0.01), AXN: 1.71 (+0.02), NYMX: 1.39 (-0.05), DRRX: 2.11 (-0.46), RIGL: 4.88 (+0.55), CAPN: 6.87 (+0.01)

The Top-Performing Biotech Stock During a Sizzling First Quarter
at The Street - Wed Apr 01, 8:30AM CDT
That was one crazy first quarter for the biotech sector. Here's where biotech stocks stand on April Fool's Day.
CRMD: 8.61 (-0.22), BIIB: 401.71 (-28.57), ESPR: 104.60 (-4.29), FMI: 46.57 (-2.16), ANTH: 5.20 (+0.31), XBI: 233.86 (-2.86), IBB: 363.70 (-3.98), TRIL: 24.21 (+2.05)

CorMedix Receives Audit Opinion with Going Concern Explanation
PR Newswire - Tue Mar 31, 5:00PM CDT
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2014, which was filed on March 12, 2015, the audited financial statements for the year ended December 31, 2014 contained in the Form 10-K contained an audit opinion from its independent registered public accounting firm which includes a going concern qualification.
CRMD: 8.61 (-0.22)

3 Small Cap Pharma Stocks Set to Surge Following Q1 Earnings - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Tue Mar 31, 1:33PM CDT
Healthcare has been a great place to invest in over the last few years, but pharmaceuticals have done even better...3 pharma stocks
CRMD: 8.61 (-0.22), IHE: 179.21 (-0.63), IYH: 158.01 (-0.59), HZNP: 31.75 (+0.97), STML: 16.58 (-0.42)

Will CorMedix (CRMD) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 31, 7:03AM CDT
Will CorMedix (CRMD) Continue to Surge Higher?
CRMD: 8.61 (-0.22)

CorMedix (CRMD): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 7:34AM CDT
CorMedix (CRMD) in the Medical – Biomed/Gene space is seeing solid earnings estimate revisions and has a great Zacks Industry Rank.
CRMD: 8.61 (-0.22)

Technical Scrutiny on Biotech Stocks -- Exact Sciences, Galena Biopharma, Alkermes, Seattle Genetics, and CorMedix
PR Newswire - Thu Mar 26, 8:00AM CDT
Editor Note: For more information about this release, please scroll to bottom.
CRMD: 8.61 (-0.22), SGEN: 37.14 (-0.36), GALE: 1.45 (+0.02), EXAS: 21.98 (-1.08), ALKS: 62.26 (-1.19)

CorMedix Announces Effectiveness of Registration Statements for Shares Underlying Publicly Traded Warrants
PR Newswire - Fri Mar 20, 7:00AM CDT
CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, today announced that the registration statements for the shares of its common stock underlying its publicly traded warrants with CUSIP number (No.21900C118) have both been declared effective by the Securities and Exchange Commission. Holders of publicly traded warrants who wish to exercise their warrants will receive freely tradable shares of common stock upon presentation of a properly completed exercise notice and full payment for exercise. As previously reported, the expiration date for these publicly traded warrants is April 30, 2015.
CRMD: 8.61 (-0.22)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aspen Dental Brings Comprehensive Care to Whiteville

Bringing Dentistry Closer to Home Now, Whiteville's dental game just got a power-up, with Aspen Dental setting up shop in town. This isn't just another practice popping up—it's a full-on dental hub offering everything from regular cleanings to emergency tooth fixes. And let’s face it, this area's diverse population needs it. The Man Behind the Chair Guess who’s at...

Striveworks: Boosting Army's AI Edge in Indo-Pacific

The world keeps marching forward, and here’s Striveworks stepping up to the plate with another big move in the military tech space. This isn't your average partnership renewal; this involves a five-year, $200 million deal to enhance battlefield AI as the U.S. Army hones its modern warfare edge in the Indo-Pacific. Now, this isn't just a battle of strategies but a battle...

PrideStaff: 8 Years Strong on Franchise Times Top 400

Where PrideStaff Stands in the Franchise Landscape Here's something the staffing world can't ignore: PrideStaff nailed it again, landing among the giants on the Franchise Times Top 400 for the eighth straight year. Sitting at number 217, this ain't just a lucky streak—this is a sustained homerun, my friends. Consistency Is Key, And They're Holding It Consider this...

Webull Faces Legal Scrutiny Over Chinese Ties

The Unfolding Drama for Webull Shareholders When you see a ticker like NASDAQ:BULL rolling off your tongue these days, it’s not just about stock prices anymore—it's a whole saga wrapped in legal and geopolitical spice. Following the recent uproar from a House China committee report, Webull found itself thrust into the spotlight for all the wrong reasons. That report...

Lupin Secures FDA Nod for Key Injectable Drug

Lupin's FDA Approval: A Strategic Play in Pharmaceuticals Ah, the thrill of a new approval! Lupin Limited has landed U.S. FDA approval for their Phytonadione Injectable Emulsion, marking a significant stride into the lucrative realm of vitamin K treatments. This approval isn't just a feather in Lupin's cap—it's a calculated move to corner a piece of the estimated $52.3...

Raken Debuts Change Orders: A Game-Changer for Builds

Construction Gets a Streamlined Boost with Raken's New Tool In construction, chaos often partners seamlessly with progress. But Raken is stepping in to shake things up a bit. This isn’t just another run-of-the-mill software update; this is Raken flexing its muscles in the construction tech arena. They’ve rolled out Change Orders, enhancing their project management...

Hexaware Teams with Anthropic for Game-Changing AI Move

A Bold AI Partnership on the Horizon Mutual back-slapping or a deal with authentic grit? Hexaware’s latest tango with Anthropic might just be the jolt enterprises need. Announced under the flickering fluorescent lights of Mumbai, London, and Iselin, Hexaware’s multi-year partnership with Anthropic thrusts Claude, their razor-sharp AI, right into the mix of...

Ajman Tourism Department Hits Internal Audit Milestone

A Nod to Standards in Ajman's Tourism Department Folks, it's not every day you see a government department get this kind of spotlight in the internal audit arena, yet here we are. The Ajman Department of Tourism, Culture and Media has snagged Full Conformance with Internal Audit Quality Standards. That’s not just some random feather in their cap but a signal flare in...

Rutter Mills Secures $13M in Virginia Injury Cases

The Stakes in Virginia When you drop nine successful injury cases on the scales and they tip over $13 million, that's a story worth dissecting. The two top dogs at Rutter Mills certainly know how to make a splash in the legal puddle, don't they? We're talking about attorneys Adam H. Lotkin and Georgina D. Montgomery here, the legal eagles behind these jaw-dropping...

Ardelyx Securities Fraud Suit: Key Investor Moves

Fraud Allegations: Ardelyx Under the Microscope Looks like Ardelyx has found itself neck-deep in trouble, facing a class action lawsuit over alleged securities fraud. This isn't just a storm in a teacup. We're talking about accusations of false and misleading statements tied to their commercial performance—statements that might have left investors holding the bag with...